SAB Biotherapeutics (SABS) Institutional Ownership $3.88 +0.62 (+19.02%) (As of 11/1/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for SAB Biotherapeutics (NASDAQ:SABS)CurrentInstitutional OwnershipPercentage7.82%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$14.26MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$37.50M Get SABS Insider Trade Alerts Want to know when executives and insiders are buying or selling SAB Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SABS Institutional Buying and Selling by Quarter Ad Porter & CompanyBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. SAB Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/17/2024 First PREMIER Bank19,386$60K0.0%N/A0.210% 5/16/2024BVF Inc. IL917,826$4.17M0.1%-90.0%9.944% 2/15/2024BVF Inc. IL9,178,282$6.31M0.2%N/A175.426% 2/14/2024Commodore Capital LP1,831,746$1.26M0.1%N/A35.024% 2/14/2024RTW Investments LP9,178,282$6.31M0.1%N/A175.493% 11/8/2023Pathstone Family Office LLC506,513$319K0.0%N/A0.968% Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/9/2023Institutional & Family Asset Management LLC192,027$159K0.0%+28.2%0.381% 2/2/2023 Silver Oak Securities Incorporated51,941$31K0.0%N/A0.121% 11/7/2022Institutional & Family Asset Management LLC149,774$105K0.0%+91.7%0.348% 10/20/2022 First PREMIER Bank807,535$566K0.2%+23.8%1.877% 8/15/2022LGL Partners LLC23,000$33K0.0%N/A0.054% 8/3/2022AE Wealth Management LLC18,700$27K0.0%N/A0.044% 7/26/2022 First PREMIER Bank652,440$946K0.3%N/A1.519% 5/9/2022Qube Research & Technologies Ltd24,179$91K0.0%+43.8%0.056% 2/14/2022Radcliffe Capital Management L.P.546,658$5.52M0.1%N/A1.257% 2/14/2022ETF Managers Group LLC13,202$105K0.0%N/A0.030% 2/14/2022Institutional & Family Asset Management LLC78,115$610K0.1%N/A0.180% 2/10/2022Qube Research & Technologies Ltd16,817$131K0.0%N/A0.039% 2/9/2022Wolverine Asset Management LLC6,602$51K0.0%N/A0.015% 2/9/2022Alps Advisors Inc.50,306$393K0.0%N/A0.116% 2/3/2022Spectrum Management Group LLC5,030$39K0.0%N/A0.012% 2/1/2022Qube Research & Technologies Ltd16,817$131K0.0%N/A0.039% 1/19/2022 First PREMIER Bank832,555$6.50M1.7%N/A1.915% 1/18/2022 Nadler Financial Group Inc.11,000$86K0.0%N/A0.025% 11/17/2021Tudor Investment Corp Et Al60,000$605K0.0%N/A0.406% (Data available from 1/1/2016 forward) SABS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SABS shares? During the previous two years, the following institutional investors and hedge funds held shares of SAB Biotherapeutics shares: RTW Investments LP ($6.31M), BVF Inc. IL ($4.17M), Commodore Capital LP ($1.26M), Pathstone Family Office LLC ($319K), Institutional & Family Asset Management LLC ($159K), and First PREMIER Bank ($60K), and Silver Oak Securities Incorporated ($31K).Learn more on SABS's institutional investors. What percentage of SAB Biotherapeutics stock is owned by institutional investors? 7.82% of SAB Biotherapeutics stock is owned by institutional investors. Learn more on SABS's institutional investor holdings. Which institutional investors have been buying SAB Biotherapeutics stock? The following institutional investors have purchased SAB Biotherapeutics stock in the last 24 months: BVF Inc. IL ($9.18M), RTW Investments LP ($9.18M), Commodore Capital LP ($1.83M), Pathstone Family Office LLC ($506.51K), Institutional & Family Asset Management LLC ($113.91K), Silver Oak Securities Incorporated ($51.94K), and First PREMIER Bank ($19.39K). How much institutional buying is happening at SAB Biotherapeutics? Institutional investors have bought a total of 20,880,062 shares in the last 24 months. This purchase volume represents approximately $14.37M in transactions. Which SAB Biotherapeutics major shareholders have been selling company stock? The following institutional investors have sold SAB Biotherapeutics stock in the last 24 months: BVF Inc. IL ($8.26M). How much institutional selling is happening at SAB Biotherapeutics? Institutional investors have sold a total of 8,260,456 shares in the last 24 months. This volume of shares sold represents approximately $37.50M in transactions. Related Companies RGLS Institutional Ownership AGEN Institutional Ownership FBIO Institutional Ownership CRIS Institutional Ownership BOLT Institutional Ownership MTEM Institutional Ownership AMGN Institutional Ownership VRTX Institutional Ownership GILD Institutional Ownership REGN Institutional Ownership This page (NASDAQ:SABS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
